Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
"The aim is to identify opportunities where we can align value and payment," on high-cost treatments, said Curt Medeiros, president of Optum Life Sciences. "There's a lot of focus on high-cost specialty areas like oncology, but also in chronic conditions that affect a broad set of the population like diabetes."
UnitedHealth and other insurers have been pushing hospitals and doctors toward new value-based reimbursement contracts for more than five years. In the last 18 months, the health insurance industry has begun to focus more on new payment deals with drugmakers to enter outcomes-based risk sharing agreements, or OBRSAs.
Medicare plan provider Humana has more than a dozen agreements with pharmaceutical companies covering nearly two dozen drugs. Aetna announced a deal with Merck earlier this year. Cigna, Humana and others have deals in place with Swiss drugmaker Novartis for its high-cost heart drug Entresto.
UnitedHealth is targeting signing another five to 10 outcomes-based deals this year.
"The level of interest in our pharma and our biotech clients has increased significantly, so the amount of opportunities out there has really grown," said Medeiros. "Cost pressure ... is probably the largest driver."
While the future of federal funding for health programs like Medicaid remains up for debate in Congress, one thing is clear — the health industry is going to come under greater pressure to lower costs. And rising specialty-drug prices have put pharmaceutical companies in the crosshairs of private payers and the government.
President Donald Trump has said he would like to see federal programs such as Medicare have the ability to negotiate lower drug prices. It is an issue that has seen some bipartisan support. For the pharmaceutical industry, OBRSAs could be a way to get out in front of potential drug-price controls.
"The collaboration between Merck and Optum will help advance both organizations' common goals of improving patient health outcomes, expanding access to innovative therapies, and ensuring the best use of health care spending," said Susan Shiff, senior vice president at Merck, in the companies' announcement.
The actual returns on the program could still be years away, but UnitedHealth and Merck say they will share their data publicly with others in the industry to develop better payment models.
"The ability to drive down the cost — ultimately to the consumer — is the long-term objective," said Medeiros. "How much, at this time, we don't know."